Compare Enveric Biosciences Inc (ENVB) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Teradyne, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Teradyne, Inc. trades at $408.68 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 9167.6× Enveric Biosciences Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Teradyne, Inc. for 37 Days on average.
| ENVB | TER | |
|---|---|---|
Market Cap | $6.80M | $62.34B |
Volume | 64,867 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $10.80 | $483.84 |
52-Week Low | $1.27 | $132.05 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | -$1.49M | $62.08B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with three consecutive earnings beats, 25.77% net margins, and 36.66% ROE. Recent product launches including Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand. Revenue is projected to grow from $3.19B in 2025 to $4.5B in 2026 according to company guidance.
TER presents a compelling growth opportunity with dominant positioning in semiconductor testing equipment and strong AI tailwinds. However, elevated valuation multiples (P/E 54.77, P/S 14.11) require continued execution. Key risks include semiconductor cycle volatility and competitive pressure from KLAC and COHU. Analyst consensus remains bullish with $461.50 price target representing 12% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
